Glioblastoma clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-05
What changed in the last 30 days
53 trials changed in the last 30 days: 1 stopped, 30 with notable changes, 22 with minor changes only.
- Notable: / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide · Recurrent or Newly Diagnosed Glioblastoma Primary and study completion pushed from Dec 2025 to Dec 2026
- Notable: Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) · Recurrent High-Grade Gliomas Primary and study completion pushed from Aug 4, 2027 to Feb 7, 2028
- Minor: M032-HSV-1 · Genetically Engineered HSV-1 Phase 1 Study · Recurrent Malignant Glioma Trial completed
- Notable: IMED-GLOW400 · Leica Microsystems Sponsored PMCF Study to Collect and Confirm Clinical Data on the Performance of the GLOW400 Device When Used in Accordance With Its Intended Use Recruitment opened
- Notable: LWBC · Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being Recruitment opened
- Minor: Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients Enrollment closed, study ongoing
- Notable: Autologous Natural Killer Cell Therapy (CHANK-101) · Recurrent Glioblastoma Start date pushed from Sep 29, 2026 to Nov 29, 2026
- Minor: PNOC016 · Fimepinostat in Treating Brain Tumors in Children and Young Adults Trial completed
- Minor: Silevertinib With Temozolomide · Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII Trial sites expanded: 34 → 38 locations
- Minor: Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG Study completion pushed from Oct 2, 2027 to Dec 11, 2027
- Minor: Chemo-immunotherapy Using Ibrutinib Plus Indoximod · Pediatric Brain Cancer Study completion pushed from Sep 30, 2028 to Dec 28, 2029
- Notable: Peds IMPACT · IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG) Start date pushed from Nov 2026 to Jan 2027
- Stopped: Verteporfin · Recurrent High Grade EGFR-Mutated Glioblastoma Trial terminated
- Notable: Zedoresertib (Debio 0123) in Combination With Temozolomide · Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma Primary endpoint(s) modified
- Minor: Treatment of Recurrent Glioblastoma Trial status changed: Recruiting → Enrolling by Invitation
- Minor: GLAD-KE · GLioma Biomarker and Safety Assessment During Dietary Ketone Elevation Subtitle: A Surgical Biomarker Discovery Study of Ketogenic Therapy in Recurrent Glioma Primary completion pushed from Oct 15, 2029 to Nov 15, 2029
- Minor: OPAL · OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma Trial sites expanded: 2 → 6 locations
- Notable: Intrathecal Azacitidine and Nivolumab · Recurrent High-grade Glioma Primary and study completion pushed from Mar 2027 to Mar 2028
- Notable: Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2) Primary completion pushed from Aug 31, 2026 to Feb 28, 2027
- Notable: Hyperpolarized Carbon-13 (13C) Pyruvate Imaging · Glioblastoma Reclassified as terminated (was completed)
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-11-02 | NCT07909811 Novel endOvascular Therapy With beVAcizumab and Cannabinoids for Glioblastoma | Unity Health Toronto new | Phase 1 |
| 2026-10-28 | NCT07902037 A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1) | Siren Biotechnology new | Phase 1/2 |
| 2026-10-08 | NCT07865195 Diffuse Gliomas in Reunion Island: Establishment of an Epidemiological… | Centre Hospitalier Universitaire de la Réunion new | |
| 2026-09-22 | NCT07832734 Metabolomics and Transcriptomics of Low- and High-Grade Gliomas | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio new | |
| 2026-09-21 | NCT07831161 Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients… | Dong-A University Hospital new | |
| 2026-09-21 | NCT07831772 REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma | University of Minnesota new | |
| 2026-09-21 | NCT07831187 Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence | First Affiliated Hospital of Wenzhou Medical University new | Phase 1/2 |
| 2026-09-15 | NCT07821112 Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated… | University of California, Irvine new | Phase 2 |
| 2026-09-10 | NCT07811297 A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | Advenchen Pharmaceuticals, LLC. new | Phase 1/2 |
| 2026-08-27 | NCT07789379 Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma | Wei Jiang new | Phase 2 |
Active trials by phase
| Early Phase 1 | 40 | |
| Phase 1 | 128 | |
| Phase 1/2 | 85 | |
| Phase 2 | 134 | |
| Phase 2/3 | 9 | |
| Phase 3 | 24 | |
| Phase 4 | 3 |
Not charted: 170 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
Mayo Clinic (16) · National Cancer Institute (NCI) (15) · City of Hope Medical Center (12) · M.D. Anderson Cancer Center (12) · University of Florida (8) · Washington University School of Medicine (8) · Nader Sanai (7) · Northwell Health (7) · Beijing Tiantan Hospital (6) · Erasmus Medical Center (6)
Get alerts when Glioblastoma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.